Assessment of Tartrate-Resistant Acid Phosphatase (TRAP) as a Bone Resorption Marker in Stage IV Breast Cancer Patients With Bone Metastasis

Exclusion Criteria

• •1. Concurrent malignancy with a second primary
• •2. Stage I, Stage II and Stage III
• •3. ECOG Performance Status 3 or 4.
• •4. Renal Failure - serum creatinine \>2.O mg/dL at screening
• •5. AST or ALT \> ULN X 3. at screening
• •6. Bilirubin \> 3.0 mg/dL at screening
• •7. Pregnant women
• •8. Prior or current bisphosphonate therapy
• •9. Any skeletal related event due to malignancy prior to study enrollment.
• •10. Patients with osteoporotic fractures prior to study enrollment.
• •11. Allergy to bisphosphonates
• •12. Any radiation therapy for the treatment of bone metastases \<4 weeks prior to study start.
• •13. Any chronic medical condition which would preclude performance or adherence to protocol requirements
• •14. Inability to provide informed consent
• •\-